Australian Clinical Labs Limited
Australian Clinical Labs Limited ACL.AX Peers
See (ACL.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACL.AX | A$2.77 | -0.36% | 540M | 18.47 | A$0.15 | +4.51% |
| SHL.AX | A$26.39 | -0.23% | 12.7B | 23.15 | A$1.14 | +4.05% |
| IDX.AX | A$2.32 | -0.85% | 863.5M | 116.00 | A$0.02 | +2.50% |
| HLS.AX | A$0.83 | N/A | 602.7M | -0.86 | -A$0.96 | +49.76% |
| MVF.AX | A$0.75 | -1.32% | 290.3M | -74.50 | -A$0.01 | +6.85% |
| GSS.AX | A$0.43 | -2.27% | 97.7M | -4.30 | -A$0.10 | N/A |
| PEB.AX | A$0.10 | +6.59% | 78.8M | -3.23 | -A$0.03 | N/A |
| MAP.AX | A$0.12 | -4.00% | 53.7M | -4.00 | -A$0.03 | N/A |
| IIQ.AX | A$0.45 | +3.45% | 50.2M | -6.43 | -A$0.07 | N/A |
| CTE.AX | A$0.75 | N/A | 36.4M | 18.63 | A$0.04 | +2.68% |
Stock Comparison
ACL.AX vs SHL.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, SHL.AX has a market cap of 12.7B. Regarding current trading prices, ACL.AX is priced at A$2.77, while SHL.AX trades at A$26.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas SHL.AX's P/E ratio is 23.15. In terms of profitability, ACL.AX's ROE is +0.18%, compared to SHL.AX's ROE of +0.07%. Regarding short-term risk, ACL.AX is more volatile compared to SHL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs IDX.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, IDX.AX has a market cap of 863.5M. Regarding current trading prices, ACL.AX is priced at A$2.77, while IDX.AX trades at A$2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas IDX.AX's P/E ratio is 116.00. In terms of profitability, ACL.AX's ROE is +0.18%, compared to IDX.AX's ROE of +0.01%. Regarding short-term risk, ACL.AX is more volatile compared to IDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs HLS.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, HLS.AX has a market cap of 602.7M. Regarding current trading prices, ACL.AX is priced at A$2.77, while HLS.AX trades at A$0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas HLS.AX's P/E ratio is -0.86. In terms of profitability, ACL.AX's ROE is +0.18%, compared to HLS.AX's ROE of -0.02%. Regarding short-term risk, ACL.AX is less volatile compared to HLS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs MVF.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, MVF.AX has a market cap of 290.3M. Regarding current trading prices, ACL.AX is priced at A$2.77, while MVF.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas MVF.AX's P/E ratio is -74.50. In terms of profitability, ACL.AX's ROE is +0.18%, compared to MVF.AX's ROE of -0.01%. Regarding short-term risk, ACL.AX is more volatile compared to MVF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs GSS.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, GSS.AX has a market cap of 97.7M. Regarding current trading prices, ACL.AX is priced at A$2.77, while GSS.AX trades at A$0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas GSS.AX's P/E ratio is -4.30. In terms of profitability, ACL.AX's ROE is +0.18%, compared to GSS.AX's ROE of -0.39%. Regarding short-term risk, ACL.AX is less volatile compared to GSS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs PEB.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, PEB.AX has a market cap of 78.8M. Regarding current trading prices, ACL.AX is priced at A$2.77, while PEB.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas PEB.AX's P/E ratio is -3.23. In terms of profitability, ACL.AX's ROE is +0.18%, compared to PEB.AX's ROE of -0.57%. Regarding short-term risk, ACL.AX is less volatile compared to PEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs MAP.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, MAP.AX has a market cap of 53.7M. Regarding current trading prices, ACL.AX is priced at A$2.77, while MAP.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas MAP.AX's P/E ratio is -4.00. In terms of profitability, ACL.AX's ROE is +0.18%, compared to MAP.AX's ROE of -0.48%. Regarding short-term risk, ACL.AX is less volatile compared to MAP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs IIQ.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, IIQ.AX has a market cap of 50.2M. Regarding current trading prices, ACL.AX is priced at A$2.77, while IIQ.AX trades at A$0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas IIQ.AX's P/E ratio is -6.43. In terms of profitability, ACL.AX's ROE is +0.18%, compared to IIQ.AX's ROE of -0.36%. Regarding short-term risk, ACL.AX is less volatile compared to IIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs CTE.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, CTE.AX has a market cap of 36.4M. Regarding current trading prices, ACL.AX is priced at A$2.77, while CTE.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas CTE.AX's P/E ratio is 18.63. In terms of profitability, ACL.AX's ROE is +0.18%, compared to CTE.AX's ROE of +1.33%. Regarding short-term risk, ACL.AX is more volatile compared to CTE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs BDX.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, BDX.AX has a market cap of 25.3M. Regarding current trading prices, ACL.AX is priced at A$2.77, while BDX.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas BDX.AX's P/E ratio is -2.30. In terms of profitability, ACL.AX's ROE is +0.18%, compared to BDX.AX's ROE of -0.90%. Regarding short-term risk, ACL.AX is more volatile compared to BDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs LDX.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, LDX.AX has a market cap of 23.2M. Regarding current trading prices, ACL.AX is priced at A$2.77, while LDX.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas LDX.AX's P/E ratio is -3.10. In terms of profitability, ACL.AX's ROE is +0.18%, compared to LDX.AX's ROE of -0.59%. Regarding short-term risk, ACL.AX is less volatile compared to LDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs RHY.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, RHY.AX has a market cap of 18.3M. Regarding current trading prices, ACL.AX is priced at A$2.77, while RHY.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas RHY.AX's P/E ratio is -6.30. In terms of profitability, ACL.AX's ROE is +0.18%, compared to RHY.AX's ROE of -0.76%. Regarding short-term risk, ACL.AX is less volatile compared to RHY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs GTG.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, GTG.AX has a market cap of 5.7M. Regarding current trading prices, ACL.AX is priced at A$2.77, while GTG.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, ACL.AX's ROE is +0.18%, compared to GTG.AX's ROE of -3.62%. Regarding short-term risk, ACL.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs IBX.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, IBX.AX has a market cap of 2.2M. Regarding current trading prices, ACL.AX is priced at A$2.77, while IBX.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas IBX.AX's P/E ratio is -0.22. In terms of profitability, ACL.AX's ROE is +0.18%, compared to IBX.AX's ROE of +0.55%. Regarding short-term risk, ACL.AX is more volatile compared to IBX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.
ACL.AX vs WFL.AX Comparison
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 540M. In comparison, WFL.AX has a market cap of 1.5M. Regarding current trading prices, ACL.AX is priced at A$2.77, while WFL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.47, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, ACL.AX's ROE is +0.18%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, ACL.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.